BHC
Price
$7.15
Change
-$0.06 (-0.83%)
Updated
Sep 10, 04:59 PM (EDT)
Capitalization
2.66B
50 days until earnings call
VTRS
Price
$10.23
Change
-$0.22 (-2.11%)
Updated
Sep 10, 04:59 PM (EDT)
Capitalization
11.94B
61 days until earnings call
Interact to see
Advertisement

BHC vs VTRS

Header iconBHC vs VTRS Comparison
Open Charts BHC vs VTRSBanner chart's image
Bausch Health Companies
Price$7.15
Change-$0.06 (-0.83%)
Volume$20.4K
Capitalization2.66B
Viatris
Price$10.23
Change-$0.22 (-2.11%)
Volume$134.52K
Capitalization11.94B
BHC vs VTRS Comparison Chart in %
Loading...
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHC vs. VTRS commentary
Sep 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a Hold and VTRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 11, 2025
Stock price -- (BHC: $7.15 vs. VTRS: $10.45)
Brand notoriety: BHC: Notable vs. VTRS: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BHC: 54% vs. VTRS: 77%
Market capitalization -- BHC: $2.66B vs. VTRS: $12.18B
BHC [@Pharmaceuticals: Generic] is valued at $2.66B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.18B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $66.22B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • BHC’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, both BHC and VTRS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 5 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • BHC’s TA Score: 5 bullish, 6 bearish.
  • VTRS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than BHC.

Price Growth

BHC (@Pharmaceuticals: Generic) experienced а -2.72% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -1.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.76%. For the same industry, the average monthly price growth was +6.58%, and the average quarterly price growth was +51.13%.

Reported Earning Dates

BHC is expected to report earnings on Oct 30, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.76% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($11.9B) has a higher market cap than BHC($2.66B). VTRS has higher P/E ratio than BHC: VTRS (236.20) vs BHC (27.50). BHC YTD gains are higher at: -11.290 vs. VTRS (-12.812). BHC has higher annual earnings (EBITDA): 3B vs. VTRS (-493.3M). BHC has more cash in the bank: 1.73B vs. VTRS (809M). VTRS has less debt than BHC: VTRS (14.8B) vs BHC (21.7B). VTRS has higher revenues than BHC: VTRS (14.1B) vs BHC (9.86B).
BHCVTRSBHC / VTRS
Capitalization2.66B11.9B22%
EBITDA3B-493.3M-608%
Gain YTD-11.290-12.81288%
P/E Ratio27.50236.2012%
Revenue9.86B14.1B70%
Total Cash1.73B809M213%
Total Debt21.7B14.8B147%
FUNDAMENTALS RATINGS
BHC vs VTRS: Fundamental Ratings
BHC
VTRS
OUTLOOK RATING
1..100
8683
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
4047
P/E GROWTH RATING
1..100
291
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is in the same range as BHC (35) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

VTRS's SMR Rating (96) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

BHC's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as VTRS (47) in the null industry. This means that BHC’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as BHC (29) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCVTRS
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
51%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 9 days ago
68%
Declines
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
54%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
YMAX12.750.16
+1.27%
YieldMax Universe Fund Of Option Inc ETF
BIB58.640.58
+0.99%
ProShares Ultra Nasdaq Biotechnology
RSMV26.100.15
+0.56%
Relative Strength Managed Volatility Strategy ETF
DUBS35.720.13
+0.37%
Aptus Large Cap Enhanced Yield ETF
USRD32.11N/A
N/A
Themes US R&D Champions ETF

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-0.29%
ELAN - VTRS
53%
Loosely correlated
-1.52%
ZTS - VTRS
46%
Loosely correlated
-1.29%
AMRX - VTRS
44%
Loosely correlated
+1.64%
EBS - VTRS
40%
Loosely correlated
+9.26%
COLL - VTRS
36%
Loosely correlated
+0.58%
More